TD Cowen Upgrades Pacira Pharmaceuticals (PCRX) to Outperform, 'Anticipate Sentiment Reversal In 2H23'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. SPY
4. WMT
5. ADI
6. ROST
7. BILL
8. MRK
9. MRNA
10. NTES

Go back to TD Cowen Upgrades Pacira Pharmaceuticals (PCRX) to Outperform, 'Anticipate Sentiment Reversal In 2H23'

Pacira BioSciences Reports Second Quarter 2023 Financial Results

August 2, 2023 8:00 AM EDT

-- Conference call today at 8:30 a.m. ET --

TAMPA, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2023.

Second Quarter 2023 Financial Highlights

Total revenues of $169.5 millionNet product sales of $135.1 million for EXPAREL, $29.3 million for ZILRETTA, and $4.4 million for iovera°Net income of $25.8 million, or $0.56 per share (basic) and $0.51 per share (diluted)Adjusted EBITDA of $54.3 million... More